Health Rounds: Boehringer drug delivers 'unprecedented' result in lung cancer study

(Reuters) - An experimental Boehringer Ingelheim drug achieved “unprecedented” benefits in patients with an advanced form of lung cancer who had already received other treatments for their disease, researchers said at the American Association for Cancer Research meeting in Chicago. The drug, zongertinib, targets the HER2 protein on cancer cell surfaces. Among 75 patients with pretreated